Anti-TNFalfa for Treatment of Isolated Gastrocnemius Myositis Related to Crohn’s Disease: A Case Report
Article Sidebar
Main Article Content
Abstract
Background: Extraintestinal manifestations are prevalent among patients diagnosed with inflammatory bowel disease (IBD). Gastrocnemius Myalgia Syndrome (GMS) is a rare manifestation of IBD. The optimal treatment regimen for GMS remains to be elucidated, and current knowledge of its histological patterns is limited.
Case presentation: We present a case of GMS associated with Crohn’s disease. The patient exhibited an original histological pattern characterized by nerve involvement, and the treatment plan involved the administration of adalimumab, leading to effective management of symptoms while reducing the need for steroids.
Conclusion: The body of knowledge concerning gastrocnemius myalgia syndrome is limited, underscoring the need for a comprehensive international registry to facilitate more accurate diagnosis and management strategies. The use of anti-TNFalfa therapy appears to be a relevant treatment approach.
Article Details
Copyright (c) 2025 Sami H.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Archives of Case Reports is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Archives of Case Reports is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA. 2023;330(10):951-65. Available from: https://doi.org/10.1001/jama.2023.15389
Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63(12):1664 9. Available from: https://doi.org/10.1136/ard.2003.012450
Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44(1):1-13. Available from: https://doi.org/10.1023/a:1026629528233
Bourikas LA, Papadakis KA. Musculoskeletal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1915-1924. Available from: https://doi.org/10.1002/ibd.20942
Catherine J, Kadhim H, Lambot F, Liefferinckx C, Meurant V, Otero Sanchez L. Crohn's disease-related 'gastrocnemius myalgia syndrome' successfully treated with infliximab: A case report. World J Gastroenterol. 2022;28(7):755-762. Available from: https://doi.org/10.3748/wjg.v28.i7.755
Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145(6):1464-78.e1-5. Available from: https://doi.org/10.1053/j.gastro.2013.10.046
Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2004;2003(1):CD003574. Available from: https://doi.org/10.1002/14651858.cd003574.pub2
Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;2008(2):CD006792. Available from: https://doi.org/10.1002/14651858.cd006792.pub2
Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, Chen L, Xie F, Curtis JR, Lewis JD. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol. 2014;12(5):811-817.e3. Available from: https://doi.org/10.1016/j.cgh.2013.06.010
Chkheidze R, Pytel P. What Every Neuropathologist Needs to Know: Peripheral Nerve Biopsy. J Neuropathol Exp Neurol. 2020 Apr 1;79(4):355-364. Available from: https://doi.org/10.1093/jnen/nlaa012
Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84(4):231-249. Available from: https://doi.org/10.1097/01.md.0000173991.74008.b0
Christopoulos C, Savva S, Pylarinou S, Diakakis A, Papavassiliou E, Economopoulos P. Localised gastrocnemius myositis in Crohn's disease. Clin Rheumatol. 2003;22(2):143-5. Available from: https://doi.org/10.1007/s10067-002-0679-9